Abstract
The gold standard for the therapy of metastatic or inoperable urothelial cancer is the combination of gemcitabine and cisplatin as first-line treatment and immunotherapy with pembrolizumab, atezolizmab or nivolumab as second-line treatment. For patients who are not eligible for standard cisplatin-containing chemotherapy, pembrolizumab and atezolizumab are first-line treatment options. In the future, targeted therapies and immunotherapeutics, e.g., in maintenance therapy, will influence the therapeutic landscape of advanced urothelial carcinoma.
Translated title of the contribution | Therapy of metastatic urothelial cancer |
---|---|
Original language | German |
Journal | Best Practice Onkologie |
Volume | 15 |
Issue number | 9 |
Pages (from-to) | 368-376 |
Number of pages | 9 |
ISSN | 0946-4565 |
DOIs | |
Publication status | Published - 01.09.2020 |
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)